Research and Markets: Dealmaking and Industry Outlook: Antivirals

DUBLIN--(BUSINESS WIRE)-- Research and Markets ( has announced the addition of Decision Resources, Inc.'s new report "Dealmaking and Industry Outlook: Antivirals" to their offering.

In February 2010, Roches CEO, Severin Schwan, reported that Tamiflu (oseltamivir) sales increased 435% over sales in 2008. Tamiflu sales were 3.2 billion Swiss francs ($3 billion) in 2009 and accounted for 7% (2.6 billion francs, $2.4 billion) of the pharmaceutical divisions sales growth the divisions sales growth was 4% without Tamiflu. This high percentage of growth was due to the global demand for antivirals active against pandemic influenza (H1N1) 2009, which certainly validated the investment that Roche had previously committed to antiviral R&D. Not every pharmaceutical company is willing to invest in this therapy area. Why not? In this report, we assess the antiviral market, its major players, and opportunities. We discuss results from a survey of U.S. infectious disease specialists and analyze the deals that companies are executing and the business strategies they are deploying.

Questions Answered in this Report:

  • Decision Resources Pharmaview analysts determined that the antiviral market was $23.4 billion in 2008. Who are the major players? What are the major brands? How will the dynamics of this market change by 2015? What new antivirals will launch and become commercially successful, according to these analysts?
  • In a 2009 interview, GlaxoSmithKline CEO Andrew Witty said, As CEO, I want this company to be a very successful drug company but not by leaving the population of Africa behind. What strategies is GSK pursuing in Africa? What are the objectives? What other pharmaceutical companies have antiviral programs in developing nations?
  • In recent years, generic products have made significant inroads into the antiviral market. Which viral diseases are most attractive to manufacturers of generics and why? What are governments doing to shift the dynamics between brand and generic antivirals where, how, and why?
  • Life-cycle management is a major business-development strategy in the antiviral industry. What deals took place in 2009? What strategies are companies using to maintain franchises and market share?
  • In 2015, the worldwide antiviral market will be one-half of the $58.6 billion anti-infective market and about one-third of the $94.1 billion cardiovascular market. What challenges does the antiviral market face? What is driving its growth?
  • A prevailing belief among industry observers is that many pharmaceutical and biotechnology companies are not interested in the antiviral market and, as a result, little research is being done and insufficient therapeutic options are available. Why should a company consider entering or expanding its presence in the antiviral market as opposed to other therapy area markets? What tactics and strategies should a company consider when entering less developed markets?


  • Viruses: Cytomegalovirus (CMV); Epstein-Barr virus (EBV); hepatitis A virus (HAV), hepatitis B virus (HBV), hepatitis C virus (HCV); herpes simplex virus (HSV-1 and HSV-2); herpes viruses 6, 7, and 8 (HHV-6, HHV-7, and HHV-8); human immunodeficiency virus (HIV); human papillomavirus (HPV); influenza virus A, influenza virus B, infl uenza (H1N1) 2009; respiratory syncytial virus (RSV); varicella-zoster virus (VZV); common cold viruses; enteroviruses; human T-lymphotropic virus (HTLV); metapneumovirus (MPV); progressive multifocal leukoencephalopathy (PML); human parainfluenza virus (HPIV); adenovirus; BK virus; JC virus; Dengue virus; arbovirus; avian influenza (H5N1); coronavirus; encephalitis viruses; West Nile virus; Saint Louis encephalitis virus; equine encephalitis viruses; rabies virus; hemorrhagic viruses; hantavirus.
  • Markets: Influenza (H1N1) 2009 pandemic market; anti-infective market; antiviral market; market size, growth; drug classes; generics; major players, major brands; worldwide sales, market share; brands that will launch soon and achieve commercial success; market drivers and constraints.
  • Generic competition: Public Library of Science (PLOS) studies; compulsory licenses; Brazilian Ministry of Health; patent expiry; generic antiretrovirals in sub-Saharan Africa and Brazil; Presidents Emergency Plan for AIDS Relief (PEPFAR); fi xed-dose combinations (FDCs); Indian manufacturers; access programs; HIV/AIDS; infl uenza; emergency use authorization by the FDA; World Health Organization (WHO); costs.
  • Primary research: Survey of 100 board-certified U.S. infectious disease specialists, their insights on unmet needs and opportunities; innovative antiviral research; monoclonal antibodies (MAbs); access to antivirals; percentage of needy patients forgoing therapy; physician recommendations on what pharmaceutical companies can do to help; generic usage; pandemic preparedness.
  • Deals: Compulsory licensing; negotiated price reductions; voluntary licenses; Gilead Access Program; life-cycle management strategies; broad-spectrum therapies; patent expiry strategy; emerging market strategy; biodefense deals; joint venture; inlicensing.
  • Expert Contributors: Peter Wittner, principal, Interpharm Consultancy, Decision Resources Pharmaview and Pharmacor analysts.
  • Outlook: Five things that are holding back the antiviral therapy area, five opportunities that could advance the antiviral therapy area.

Key Terms for This Report: Access programs, Antivirals, Brazil, Business development, Fixed-dose combination (FDC), Generic competition, Hepatitis, H1N1, HIV AIDS, Indian manufacturer, Least developed countries, Opportunities, Pandemic, Strategic planning, Sub-Saharan Africa

Key Topics Covered:

  • Executive Summary
  • Was It Fear Mongering?
  • Antiviral Market
  • Competition from Generics
  • Survey of Board-Certified U.S. Infectious Disease Specialists
  • Select Deal Structures and Strategies
  • Outlook
  • Expert Commentaries

Companies Mentioned:

  • Abbott Laboratories
  • Alkem Laboratories
  • Amarillo Biosciences
  • Asahi Kasei Pharma
  • Aspen Pharmacare
  • Astellas Pharma
  • AstraZeneca
  • Aurobindo Pharma
  • Avexa
  • Barr Laboratories
  • BioAlliance Pharma
  • BioChem Solutions
  • BioCryst Pharmaceuticals
  • BioPartners
  • Boehringer Ingelheim
  • Brazilian Ministry of Health
  • Bristol-Myers Squibb
  • Calmune
  • Center of High Technologies ChemRar (CHT ChemRar)
  • Centers for Disease Control and Prevention
  • Chugai Pharmaceutical
  • + many more

For more information visit


Research and Markets
Laura Wood, Senior Manager,
[email protected]
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716


INDUSTRY KEYWORDS:   Health  Pharmaceutical